3D Bioprinting as an In Vitro Tool to Model the Tumor Microenvironment.
文献摘要
Three‑dimensional (3D) bioprinting has rapidly emerged as a powerful strategy for engineering physiologically relevant tumor microenvironment (TME) models that overcome the limitations of traditional 2D cultures and animal systems. The TME is a highly dynamic and heterogeneous ecosystem composed of malignant, stromal, immune, and vascular cells embedded within a biochemically and mechanically complex extracellular matrix (ECM). These components collectively regulate tumor progression, immune evasion, metastasis, and therapeutic resistance. Conventional preclinical models fail to capture this complexity, contributing to poor clinical translation of oncology therapeutics. Advances in extrusion‑based, inkjet, laser‑assisted, and stereolithographic bioprinting now enable spatially organized, multicellular constructs with tunable biochemical and biophysical cues that more accurately recapitulate TME architecture and function. Complementary innovations in biomaterials, microfluidics, and computational modeling further expand the capabilities of bioprinted systems for drug screening, mechanistic studies, and personalized medicine. This review summarizes the cellular and acellular components of the TME, outlines major bioprinting technologies and biomaterial strategies, and highlights emerging applications in cancer modeling. We also identify key research gaps and opportunities that must be addressed to advance bioprinted TME platforms toward robust, standardized, and clinically meaningful tools for precision oncology.